Potent neutralization by monoclonal human IgM against SARS‐CoV‐2 is impaired by class switch
暂无分享,去创建一个
T. Derfuss | A. Buser | G. Zimmer | E. Galli | A. Egli | N. Khanna | T. Roloff | Tobias Mühlethaler | R. Boss | L. Infanti | Giuliano Berloffa | I. Callegari | Sebastian Holdermann | N. Sanderson | Mika Schneider | S. Holdermann
[1] M. Seeger,et al. Biparatopic sybodies neutralize SARS‐CoV‐2 variants of concern and mitigate drug resistance , 2022, EMBO reports.
[2] B. Becher,et al. Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia , 2022, Annals of neurology.
[3] Larance Ronsard,et al. Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses , 2021, Science Immunology.
[4] R. Newman,et al. Endophilin A2 regulates B‐cell endocytosis and is required for germinal center and humoral responses , 2021, EMBO reports.
[5] William T. Harvey,et al. SARS-CoV-2 variants, spike mutations and immune escape , 2021, Nature Reviews Microbiology.
[6] G. Kochs,et al. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants , 2021, Nature Communications.
[7] M. Beltramello,et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 , 2021, Cell.
[8] Peter D. Crompton,et al. Multimeric antibodies from antigen-specific human IgM+ memory B cells restrict Plasmodium parasites , 2021, The Journal of experimental medicine.
[9] M. Battegay,et al. SARS-CoV-2 outbreak in a tri-national urban area is dominated by a B.1 lineage variant linked to a mass gathering event , 2021, PLoS pathogens.
[10] Larance Ronsard,et al. Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses , 2021, bioRxiv.
[11] C. Rice,et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA , 2020, Science Translational Medicine.
[12] M. Battegay,et al. Epidemiology and precision of SARS‐CoV‐2 detection following lockdown and relaxation measures , 2020, Journal of medical virology.
[13] J. Beeson,et al. Complement Factors in COVID-19 Therapeutics and Vaccines , 2020, Trends in Immunology.
[14] L. Carter,et al. Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19 , 2020, Cell.
[15] B. Keyt,et al. Structure, Function, and Therapeutic Use of IgM Antibodies , 2020, Antibodies.
[16] D. Lauffenburger,et al. Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality , 2020, Cell.
[17] C. Rice,et al. LY6E impairs coronavirus fusion and confers immune control of viral disease , 2020, Nature Microbiology.
[18] C. Rice,et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants , 2020, bioRxiv.
[19] G. Zimmer,et al. Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using Propagation-Defective Vesicular Stomatitis Virus Pseudotypes , 2020, Vaccines.
[20] D. Fremont,et al. Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2 , 2020, Cell Host & Microbe.
[21] L. Pirofski,et al. A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition , 2020, Cell Host & Microbe.
[22] R. Wallis,et al. Rationale for targeting complement in COVID‐19 , 2020, EMBO molecular medicine.
[23] C. Rice,et al. Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.
[24] M. Malim,et al. Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings , 2020, medRxiv.
[25] Xiangxi Wang,et al. Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection , 2020, bioRxiv.
[26] Charlotte M. Deane,et al. CoV-AbDab: the Coronavirus Antibody Database , 2020, bioRxiv.
[27] M. V. van Breemen,et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.
[28] B. Becher,et al. GM-CSF and CXCR4 Define a T Helper Cell Signature in Multiple Sclerosis , 2019, Nature Medicine.
[29] A. Koster,et al. Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b , 2019, Proceedings of the National Academy of Sciences.
[30] John M. Lindner,et al. Antigen Extraction and B Cell Activation Enable Identification of Rare Membrane Antigen Specific Human B Cells , 2019, Front. Immunol..
[31] G. Alter,et al. Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine , 2019, Front. Immunol..
[32] Honglin Chen,et al. An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency , 2019, Theranostics.
[33] S. Fortune,et al. Beyond binding: antibody effector functions in infectious diseases , 2017, Nature Reviews Immunology.
[34] Veronika Chromikova,et al. Evaluating the bottlenecks of recombinant IgM production in mammalian cells , 2015, Cytotechnology.
[35] J. Molloy,et al. B Cells Use Mechanical Energy to Discriminate Antigen Affinities , 2013, Science.
[36] R. Loh,et al. Quantitative serum immunoglobulin tests. , 2013, Australian Family Physician.
[37] Michael Meyer-Hermann,et al. Germinal center B cells govern their own fate via antibody feedback , 2013, The Journal of experimental medicine.
[38] A. Casadevall,et al. Variable Region Identical Immunoglobulins Differing in Isotype Express Different Paratopes* , 2012, The Journal of Biological Chemistry.
[39] Niels H. Wulff,et al. Monte Carlo simulation of the Spearman-Kaerber TCID50 , 2012, Journal of Clinical Bioinformatics.
[40] G. Zimmer,et al. A Vesicular Stomatitis Virus Replicon-Based Bioassay for the Rapid and Sensitive Determination of Multi-Species Type I Interferon , 2011, PloS one.
[41] D. Fremont,et al. Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus. , 2009, Cell host & microbe.
[42] Robert Gentleman,et al. ShortRead: a bioconductor package for input, quality assessment and exploration of high-throughput sequence data , 2009, Bioinform..
[43] Michel C Nussenzweig,et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. , 2008, Journal of immunological methods.
[44] Masanori Suzuki,et al. EGassembler: online bioinformatics service for large-scale processing, clustering and assembling ESTs and genomic DNA fragments , 2006, Nucleic Acids Res..
[45] J. Goldman,et al. B Cell Ligand Discrimination Through a Spreading and Contraction Response , 2006, Science.
[46] M. Oda,et al. Segmental flexibility and avidity of IgM in the interaction of polyvalent antigens. , 2004, Molecular immunology.
[47] M. Neuberger,et al. B cells acquire antigen from target cells after synapse formation , 2001, Nature.
[48] M. Neuberger,et al. Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. , 1998, Immunity.
[49] N. Dimmock,et al. Mechanisms of neutralization of a nairovirus (Dugbe virus) by polyclonal IgG and IgM. , 1992, Journal of General Virology.
[50] J. Larrick,et al. Probing the normal and autoimmune B cell repertoire with Epstein-Barr virus. Frequency of B cells producing monoreactive high affinity autoantibodies in patients with Hashimoto's disease and systemic lupus erythematosus. , 1988, Journal of immunology.